Department of Veterinary Clinical Sciences, College of Veterinary Medicine, The Ohio State University, Columbus, OH, USA.
J Vet Intern Med. 2011 May-Jun;25(3):511-7. doi: 10.1111/j.1939-1676.2011.0697.x. Epub 2011 Apr 12.
Appendicular osteosarcoma (OSA), the most common bone tumor in dogs, is typically treated by amputation and adjuvant chemotherapy. Despite numerous efforts, the median survival time (MST) for dogs receiving a platinum compound, doxorubicin, or a combination of these remains at 8-12 months. Evidence from studies in mice suggests that gemcitabine has activity against OSA in vivo. Our preliminary work demonstrated that the addition of low-dosage (10 mM) gemcitabine to carboplatin resulted in synergistic inhibition of OSA cell viability in vitro.
The purpose of the following study was to determine whether the addition of low-dosage (2 mg/kg) gemcitabine to carboplatin chemotherapy in dogs with OSA after amputation would improve MST over carboplatin monotherapy.
Fifty dogs with histologically confirmed appendicular OSA.
Dogs were treated prospectively with amputation and up to 4 dosages of carboplatin and gemcitabine in combination every 3 weeks.
The chemotherapeutic regimen was well tolerated with only 5 episodes of grade 3 or 4 hematologic toxicity. The median disease-free interval (DFI) was 203 days and the MST was 279 for all dogs in this study. The 1- and 2-year survival rates were 29.5 and 11.3%, respectively. Dogs with proximal humeral OSA had a shorter median DFI (P = .04) compared with dogs with OSA in other locations.
These results are comparable to those reported for carboplatin monotherapy indicating that the addition of gemcitabine to carboplatin in dogs with appendicular OSA does not appear to improve outcome.
附肢骨肉瘤（OSA）是犬最常见的骨肿瘤，通常通过截肢和辅助化疗进行治疗。尽管进行了大量努力，但接受铂化合物顺铂、多柔比星或两者联合治疗的犬的中位生存时间（MST）仍为 8-12 个月。来自小鼠研究的证据表明，吉西他滨在体内对 OSA 具有活性。我们的初步研究表明，低剂量（10mM）吉西他滨与卡铂联合使用可协同抑制体外 OSA 细胞活力。
本研究的目的是确定在截肢后患有 OSA 的犬中添加低剂量（2mg/kg）吉西他滨是否会提高卡铂单药化疗的 MST。
50 只经组织学证实患有附肢 OSA 的犬。
前瞻性地对犬进行截肢和多达 4 个剂量的卡铂和吉西他滨联合治疗，每 3 周一次。
该化疗方案耐受性良好，仅有 5 例出现 3 级或 4 级血液学毒性。本研究中所有犬的无病间隔（DFI）中位数为 203 天，MST 为 279 天。1 年和 2 年的存活率分别为 29.5%和 11.3%。与其他部位患有 OSA 的犬相比，肱骨近端 OSA 犬的中位 DFI 更短（P=0.04）。
这些结果与卡铂单药治疗的报告结果相当，表明在患有附肢 OSA 的犬中添加吉西他滨似乎不能改善结果。
